Clinical trial
Clinical Evaluation of BW430C in Epilepsy
NCT00395694 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00395694 |
|---|---|
| Title | Clinical Evaluation of BW430C in Epilepsy |
| Official title | Clinical Evaluation of BW430C in Epilepsy<Phase III Study> |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | lamictal |
| Enrollment | 102 |
| Start date | Aug 7, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 26, 2009 |
| First posted | Nov 3, 2006 |
| Last update posted | Sep 26, 2018 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: